EISAI INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

First Posted Date
2020-07-13
Last Posted Date
2024-07-30
Lead Sponsor
Eisai Inc.
Target Recruit Count
1400
Registration Number
NCT04468659
Locations
🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Ohio State University, Columbus, Ohio, United States

🇺🇸

Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland, Ohio, United States

and more 110 locations

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

First Posted Date
2020-03-09
Last Posted Date
2024-12-09
Lead Sponsor
Eisai Inc.
Target Recruit Count
142
Registration Number
NCT04300556
Locations
🇺🇸

Chattanooga's Program In Women's Oncology, Chattanooga, Tennessee, United States

🇺🇸

Arizona Clinical Research Center - Hunt - PPDS, Tucson, Arizona, United States

🇺🇸

University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States

and more 50 locations

A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder

First Posted Date
2020-03-09
Last Posted Date
2020-10-27
Lead Sponsor
Eisai Inc.
Target Recruit Count
37
Registration Number
NCT04300569
Locations
🇺🇸

ATP Clinical Research, Costa Mesa, California, United States

🇺🇸

Pacific Research Network Inc, San Diego, California, United States

🇺🇸

Panax Clinical Research, Miami Lakes, Florida, United States

and more 3 locations

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

First Posted Date
2020-02-27
Last Posted Date
2024-12-05
Lead Sponsor
Eisai Inc.
Target Recruit Count
31
Registration Number
NCT04288089
Locations
🇬🇧

Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

🇺🇸

Saint Luke's Cancer Institute, Kansas City, Missouri, United States

🇬🇧

Sarah Cannon Research Institute UK - SCRI, London, United Kingdom

and more 4 locations

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-01-18
Last Posted Date
2023-04-06
Lead Sponsor
Eisai Inc.
Target Recruit Count
72
Registration Number
NCT04231513
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

🇺🇸

California Clinical Trials Medical Group/Parexel International, Glendale, California, United States

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

First Posted Date
2019-11-06
Last Posted Date
2024-07-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
81
Registration Number
NCT04154189
Locations
🇺🇸

Loma Linda University Medical Center, Loma Linda, California, United States

🇺🇸

University of Mississippi Medical Center, Jackson, Mississippi, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 81 locations

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2019-10-30
Last Posted Date
2024-03-07
Lead Sponsor
Eisai Inc.
Target Recruit Count
24
Registration Number
NCT04144140
Locations
🇺🇸

University of Pittsburgh Medical Center and Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

and more 10 locations

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Phase 1
Withdrawn
Conditions
Interventions
First Posted Date
2019-09-30
Last Posted Date
2020-12-14
Lead Sponsor
Eisai Inc.
Registration Number
NCT04109092
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

UCLA, Santa Monica, California, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 6 locations

A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-07-18
Last Posted Date
2019-12-03
Lead Sponsor
Eisai Inc.
Target Recruit Count
8
Registration Number
NCT04023877
Locations
🇺🇸

Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath